KindlyMD, Inc. (NASDAQ:NAKA) Receives Average Recommendation of “Hold” from Brokerages

Shares of KindlyMD, Inc. (NASDAQ:NAKA) have received an average rating of “Hold” from the five ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $30.00.

Several analysts recently weighed in on NAKA shares. Maxim Group cut their price target on KindlyMD from $60.00 to $30.00 and set a “buy” rating on the stock in a research note on Monday, April 6th. TD Cowen started coverage on KindlyMD in a research note on Friday, April 10th. They issued a “buy” rating and a $40.00 price target on the stock. Weiss Ratings upgraded KindlyMD from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Wall Street Zen upgraded KindlyMD to a “sell” rating in a research note on Saturday, May 23rd. Finally, B. Riley Financial cut their target price on KindlyMD from $40.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, February 23rd.

KindlyMD Stock Up 11.8%

KindlyMD stock opened at $6.26 on Friday. The company has a market capitalization of $108.92 million, a P/E ratio of -0.14 and a beta of 17.12. The stock’s 50 day moving average is $8.14 and its 200 day moving average is $13.02. KindlyMD has a twelve month low of $4.50 and a twelve month high of $995.60.

KindlyMD (NASDAQ:NAKA) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($15.20) earnings per share for the quarter. The company had revenue of $2.68 million during the quarter. KindlyMD had a negative return on equity of 81.32% and a negative net margin of 7,397.12%. As a group, equities analysts expect that KindlyMD will post -16.8 EPS for the current year.

Insider Buying and Selling

In other KindlyMD news, CEO David F. Bailey bought 55,115 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were acquired at an average cost of $5.62 per share, for a total transaction of $309,746.30. Following the purchase, the chief executive officer owned 3,175,476 shares in the company, valued at approximately $17,846,175.12. This trade represents a 1.77% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders acquired 191,448 shares of company stock worth $992,908. Company insiders own 24.49% of the company’s stock.

Institutional Trading of KindlyMD

Several institutional investors have recently added to or reduced their stakes in NAKA. Alyeska Investment Group L.P. purchased a new stake in KindlyMD during the 4th quarter valued at $8,993,000. ParaFi Capital LP purchased a new position in shares of KindlyMD in the 3rd quarter worth $443,055,000. Hunting Hill Global Capital LLC purchased a new position in shares of KindlyMD in the 4th quarter worth $4,672,000. RK Capital Management LLC FL purchased a new position in shares of KindlyMD in the 3rd quarter worth $239,052,000. Finally, Yorkville Advisors Global LP purchased a new position in shares of KindlyMD in the 3rd quarter worth $231,942,000.

Key KindlyMD News

Here are the key news stories impacting KindlyMD this week:

• Positive Sentiment: CEO David Bailey bought 31,500 more shares at $5.58, adding to a recent series of insider purchases that may reassure investors about the company’s outlook. Article Title
• Positive Sentiment: Maxim Group reiterated a Buy rating on NAKA with a $30 price target, and its newer earnings forecasts imply a possible improvement in results over time. Article Title
• Neutral Sentiment: The analyst estimates still call for losses in the next several quarters, though they show a potential path toward profitability in fiscal 2027. Article Title
• Negative Sentiment: KindlyMD’s latest reported quarter showed a large EPS loss and very weak profitability, underscoring that the business remains highly speculative despite the recent stock strength. Article Title

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.